ArticleJournal of biochemical and molecular toxicology2026
LINC01352 Inhibits Lung Adenocarcinoma Progression by Modulating the miR-425-5p/SRSF11 Pathway.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LINC01352 Inhibits Lung Adenocarcinoma Progression by Modulating the miR-425-5p/SRSF11 Pathway.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD), as the most common subtype of non-samll cell lung cancer, is highly malignant and associated with a poor overall prognosis for patients, making it imperative to further investigate its molecular mechanisms of pathogenesis. This study aims to clarify the role of LINC01352 in the malignant progression of lung adenocarcinoma (LUAD). LINC01352 expression in LUAD versus normal tissue was analyzed using StarBase and GEPIA databases. RT-qPCR was employed to explore the levels of LINC01352, miR-425-5p, and SRSF11 in102 clinically collected LUAD tissue samples. Cell proliferation was assessed using the CCK-8 assay, while cell migration and invasion capabilities were examined via Transwell experiments. DLR and RIP experiments were performed to validate the target relationships between LINC01352 and miR-425-5p, as well as SRSF11 and miR-425-5p. The level of LINC01352 decreased in LUAD, and enhancing LINC01352 inhibited the malignant phenotype of LUAD cells. LINC01352 binds to miR-425-5p. Increasing miR-425-5p expression offset the inhibitory impacts of LINC01352 overexpression on the malignant behavior of LUAD cells. Furthermore, SRSF11 is a target of miR-425-5p, and its expression in LUAD tissues showed a significant inverse relationship with miR-425-5p. LINC01352 exerts tumor-suppressive function in LUAD through the miR-425-5p/SRSF11 axis, thereby inhibiting malignant progression of LUAD. This study indicates that targeting the LINC01352/miR-425-5p/SRSF11 pathway may represent a promising therapeutic strategy for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.